Advanced Filter

Filter by Group

Filter by Market Availability

Clear
Displaying drugs 2226 - 2250 of 15152 in total

Pancrelipase amylase

Pancrelipase, in general, is composed of a mixture of pancreatic enzymes which include amylases, lipases, and proteases. These enzymes are extracted from porcine pancreatic glands. The amylases are enzymes that help in the chemical process of digestion by hydrolizing starch into more available saccharide forms. The pancrelipase amylase is a...
Approved
Matched Description: … Pancrelipase, in general, is composed of a mixture of pancreatic enzymes which include amylases, lipases, and ... mixture, including pancrelipase amylase, was developed by Ortho-McNeil-Janssen Pharmaceuticals, Inc and ... [T177] The pancrelipase amylase is a single polypeptide chain containing two SH groups and four disulfide …
Matched Categories: … Enzymes and Coenzymes …

Corynebacterium diphtheriae CRM197 protein

Approved
Matched Categories: … Amino Acids, Peptides, and Proteins …

Menadione

A synthetic naphthoquinone without the isoprenoid side chain and biological activity, but can be converted to active vitamin K2, menaquinone, after alkylation in vivo.
Approved
Nutraceutical
Matched Description: … A synthetic naphthoquinone without the isoprenoid side chain and biological activity, but can be converted …
Matched Categories: … Blood and Blood Forming Organs ... Diet, Food, and Nutrition …

Dalbavancin

Dalbavancin is a second-generation lipoglycopeptide antibiotic that was designed to improve on the natural glycopeptides currently available, such as vancomycin and teicoplanin [A4072, A4073]. Modifications from these older glycoprotein classes facilitated a similar mechanism of action for dalbavancin but with increased activity and once-weekly dosing [FDA Label, F2356, A4072, A4073]....
Approved
Investigational
Matched Description: … S. constellatus), and Enterococcus faecalis (vancomycin susceptible strains) [FDA Label, F2356]. ... Its use is indicated for the treatment of acute bacterial skin and skin structure infections (ABSSSI) ... antibiotic that was designed to improve on the natural glycopeptides currently available, such as vancomycin and …
Matched Categories: … Amino Acids, Peptides, and Proteins …

Nivolumab

Nivolumab is a fully human IgG4 antibody targeting the immune checkpoint programmed death receptor-1 (PD-1). This antibody was produced entirely in mice and grafted onto human kappa and IgG4 Fc region with the mutation S228P for additional stability and reduced variability. It was developed by Bristol Myers Squibb. Nivolumab was...
Approved
Matched Description: … [L12129] This antibody was produced entirely in mice and grafted onto human kappa and IgG4 Fc region ... with the mutation _S228P_ for additional stability and reduced variability. …
Matched Categories: … nivolumab and relatlimab ... Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …

Trospium

Trospium is an antispasmodic agent used to treat the symptoms of overactive bladder, a condition that causes the bladder muscles to contract uncontrollably. An overactive bladder leads to an increased urge to urinate, frequent urination, and sometimes, loss of control over urination. Trospium is manufactured by Indevus Pharmaceutical Inc. and...
Approved
Matched Description: … [L6208] An overactive bladder leads to an increased urge to urinate, frequent urination, and sometimes ... [L6208] Trospium is manufactured by _Indevus Pharmaceutical Inc._ and was granted FDA approval in 2007 …
Matched Categories: … trospium and analgesics ... Alimentary Tract and Metabolism ... Genito Urinary System and Sex Hormones ... Drugs for Urinary Frequency and Incontinence …

Obinutuzumab

Obinutuzumab is a humanized monoclonal antibody used as a combination treatment with chlorambucil to treat patients with untreated chronic lymphocytic leukemia. It was approved by the FDA in November 2013 and is marketed under the brand name Gazyva. There is a black box warning of fatal Hepatitis B Virus (HBV)...
Approved
Investigational
Matched Description: … It was approved by the FDA in November 2013 and is marketed under the brand name Gazyva. ... There is a black box warning of fatal Hepatitis B Virus (HBV) reactivation and fatal Progressive Multifocal …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …

Cefpodoxime

Cefpodoxime is an oral third generation cephalosporin antibiotic with effectiveness against most Gram positive and Gram negative bacteria. Commonly used to treat acute otitis media, pharyngitis, and sinusitis, cefpodoxime proxetil is a prodrug which is absorbed and de-esterified by the intestinal mucosa to Cefpodoxime.
Approved
Vet approved
Matched Iupac: … 2-(methoxyimino)acetamido]-3-(methoxymethyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid …
Matched Description: … which is absorbed and de-esterified by the intestinal mucosa to Cefpodoxime. ... is an oral third generation cephalosporin antibiotic with effectiveness against most Gram positive and ... Commonly used to treat acute otitis media, pharyngitis, and sinusitis, cefpodoxime proxetil is a prodrug …

Acarbose

Acarbose is a complex oligosaccharide that acts as an inhibitor of several enzymes responsible for the breakdown of complex carbohydrates in the intestines. It inhibits both pancreatic alpha-amylase and membrane-bound alpha-glucosidases - including intestinal glucoamylase, sucrase, maltase, and isomaltase - which are responsible for the metabolism of complex starches and...
Approved
Investigational
Matched Description: … starches and oligo-, tri-, and disaccharides into absorbable simple sugars. ... the subsequent postprandial increase in blood glucose and insulin levels. ... It inhibits both pancreatic alpha-amylase and membrane-bound alpha-glucosidases - including intestinal …
Matched Categories: … metformin and acarbose ... Alimentary Tract and Metabolism …

Ublituximab

CD20, an antigen expressed by various B and T cells, is an attractive therapeutic target in various cancers and autoimmune conditions.[A244195, A244200, A244205] Monoclonal antibodies for B cell depletion rely on their binding affinity and ability to clear bound cells through mechanisms such as antibody-dependent cellular cytotoxicity (ADCC), mediated by...
Approved
Investigational
Matched Description: … and autoimmune conditions. ... CD20, an antigen expressed by various B and T cells, is an attractive therapeutic target in various cancers ... A244195, A244200, A244205] Monoclonal antibodies for B cell depletion rely on their binding affinity and …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents …

Inebilizumab

Inappropriate growth of or self-directed antibody production by B-cells is the etiological underpinning of a variety of conditions, including the multiple sclerosis-like neurological condition neuromyelitis optica spectrum disorder (NMOSD).[A214283, A214286] Inebilizumab is a humanized afucosylated monoclonal IgG1 antibody directed against the broadly expressed B-cell surface antigen CD19. Inebilizumab is cytolytic,...
Approved
Investigational
Matched Description: … Inebilizumab is cytolytic, resulting in B-cell depletion and offering therapeutic benefit to patients ... [L14315] Given its mechanism of action and good safety profile, it may prove useful in the treatment …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents …

Chloramphenicol succinate

Chloramphenicol succinate is an ester prodrug of chloramphenicol. Chloramphenicol is a bacteriostatic antibiotic. Use of chloramphenicol succinate and chloramphenicol has decreased due to the risk of potentially fatal blood dyscrasias. Chloramphenicol succinate was granted FDA approval on 20 February 1959.
Approved
Matched Iupac: … 4-[(2R,3R)-2-(2,2-dichloroacetamido)-3-hydroxy-3-(4-nitrophenyl)propoxy]-4-oxobutanoic acid …
Matched Description: … [A204065] Use of chloramphenicol succinate and chloramphenicol has decreased due to the risk of potentially …

Teprotumumab

Teprotumumab is a fully human IgG1 monoclonal antibody directed against the human insulin-like growth factor-1 receptor. Following a clinical trial in which its efficacy in the treatment of thyroid eye disease (TED) was assessed, it received "breakthrough therapy" designation from the FDA in 2016 and was approved by the FDA...
Approved
Investigational
Matched Description: … tissue remodeling behind the eye, and previous treatment options typically involved multiple invasive ... disease (TED) was assessed, it received "breakthrough therapy" designation from the FDA in 2016[A190129] and ... Thyroid eye disease is a potentially debilitating complication of Graves' Disease involving inflammation and …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents …

Ravulizumab

Ravulizumab is a potent and selective complement 5 (C5) inhibitor. It is a humanized monoclonal IgG2/4 kappa antibody produced in Chinese hamster ovary (CHO) cells. Ravulizumab was engineered from eculizumab, another complement inhibitor, to increase the duration of action and reduce the frequency of drug administration. It works by blocking...
Approved
Investigational
Matched Description: … Ravulizumab is a potent and selective complement 5 (C5) inhibitor. ... atypical hemolytic uremic syndrome in children and adults. ... was engineered from [eculizumab], another complement inhibitor, to increase the duration of action and …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents …

Eslicarbazepine acetate

Eslicarbazepine acetate (ESL) is an anticonvulsant medication approved for use in Europe, the United States and Canada as an adjunctive therapy for partial-onset seizures that are not adequately controlled with conventional therapy. Eslicarbazepine acetate is a prodrug that is rapidly converted to eslicarbazepine, the primary active metabolite in the body....
Approved
Matched Description: … Eslicarbazepine acetate (ESL) is an anticonvulsant medication approved for use in Europe, the United States and ... Eslicarbazepine acetate is marketed as Aptiom in North America and Zebinix or Exalief in Europe. ... , but it is known that it does exert anticonvulsant activity by inhibiting repeated neuronal firing and …
Matched Categories: … Eslicarbazepine and prodrugs …

Stem bromelain

The primary therapeutic use for which stem bromelain is currently and formally indicated is as a burn wound eschar debridement agent that has been approved by the EMA since 2012 and marketed under the brand name Nexobrid [FDA Label]. Bromelain itself belongs to a category of protein-digesting enzymes that are...
Approved
Investigational
Matched Description: … Although both fruit and stem bromelain are prepared differently and contain different enzymatic compositions ... The primary therapeutic use for which stem bromelain is currently and formally indicated is as a burn ... wound eschar debridement agent that has been approved by the EMA since 2012 and marketed under the brand …
Matched Categories: … Enzymes and Coenzymes …

Ferric pyrophosphate citrate

Ferric pyrophosphate citrate is a soluble iron replacement product. Free iron presents several side effects as it can catalyze free radical formation and lipid peroxidation as well as the presence of interactions of iron in plasma. The ferric ion is strongly complexed by pyrophosphate and citrate. FPC is categorized in...
Approved
Investigational
Matched Iupac: … tetrairon(3+) bis((phosphonooxy)phosphonic acid) tris(2-hydroxypropane-1,2,3-tricarboxylate) (hydrogen …
Matched Description: … The ferric ion is strongly complexed by pyrophosphate and citrate. ... Free iron presents several side effects as it can catalyze free radical formation and lipid peroxidation …
Matched Categories: … Enzymes and Coenzymes …

Tofersen

Tofersen is under an intrathecally administered antisense oligonucleotide targeting the mutated SOD1 gene that causes amyotrophic lateral sclerosis (ALS). Although there were various causes of ALS, 2% of ALS cases are due to SOD1 mutations, with more than 200 SOD1 mutations documented.[A259028,A259033] Tofersen was granted accelerated approval from the FDA...
Approved
Investigational
Matched Description: … [A259023] However, it could potentially be due to the short timeframe of tofersen treatment, and more ... [L46133] Tofersen demonstrated efficacy in reducing the concentration of SOD1 in CSF and of neurofilament …
Matched Categories: … Nucleic Acids, Nucleotides, and Nucleosides …

Acetylcholine

A neurotransmitter. Acetylcholine in vertebrates is the major transmitter at neuromuscular junctions, autonomic ganglia, parasympathetic effector junctions, a subset of sympathetic effector junctions, and at many sites in the central nervous system. It is generally not used as an administered drug because it is broken down very rapidly by cholinesterases,...
Approved
Investigational
Matched Description: … autonomic ganglia, parasympathetic effector junctions, a subset of sympathetic effector junctions, and …
Matched Categories: … Antiglaucoma Preparations and Miotics …

Secukinumab

Secukinumab is a fully human monoclonal IgG1/κ antibody against interleukin-17A (IL-17A), a proinflammatory cytokine implicated in various chronic immune-mediated inflammatory disorders, such as plaque psoriasis. By blocking the actions of IL-17A, secukinumab works to inhibit the pro-inflammatory pathways that drive immune-mediated inflammatory disorders. Following its first global approval in Japan...
Approved
Matched Description: … in Japan in December 2014, secukinumab was approved by the European Commission on January 15, 2015, and ... chronic inflammatory conditions, such as plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents …

Pegfilgrastim

Pegfilgrastim is a PEGylated form of the recombinant human granulocyte colony-stimulating factor (G-CSF) analogue, filgrastim. The drug is approved for use to decrease the incidence of infection, as manifested by febrile neutropenia, in susceptible patients with with non-myeloid cancer receiving myelosuppressive anti-cancer treatment. Although the risk of developing febrile neutropenia...
Approved
Matched Description: … pharmacokinetic profile and conditions of use. ... than 20% in many readily used chemotherapy regimens,[A248855] infections pose risks of hospitalization and ... Pelmeg, Udenyca, Ziextenzo, Grasustek, Fylnetra, Stimufend) by Health Canada, European Union (EU), and …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... Intercellular Signaling Peptides and Proteins …

Tislelizumab

Tislelizumab is a humanized monoclonal IgG4 antibody against programmed death receptor-1 (PD-1). It was engineered to have a nullified Fc portion, thus minimizing binding to FcγR on macrophages and limiting treatment resistance via antibody-dependent phagocytosis. By blocking PD-L1/PD-L2–mediated cell signaling, tislelizumab restores T-cell function through cytokine production, resulting in immune-mediated...
Approved
Investigational
Matched Description: … It was engineered to have a nullified Fc portion, thus minimizing binding to FcγR on macrophages and ... [A262919] Tislelizumab is generally well tolerated with manageable and mild-to-moderate adverse effects …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …

Retifanlimab

Retifanlimab is a humanized IgG4 kappa monoclonal antibody that binds to the programmed death receptor-1 (PD-1), blocking PD-1 interaction with its ligands, programmed death-ligand 1 (PD-L1) and programmed death-ligand 2 (PD-L2). By blocking the PD-1/PD-L1/2 pathway, retifanlimab potentiates T-cell activity and boosts the immune response against cancer cells. Other monoclonal...
Approved
Investigational
Matched Description: … By blocking the PD-1/PD-L1/2 pathway, retifanlimab potentiates T-cell activity and boosts the immune ... death receptor-1 (PD-1), blocking PD-1 interaction with its ligands, programmed death-ligand 1 (PD-L1) and ... [L45603] Other monoclonal antibodies that block PD-1 include [pembrolizumab], [nivolumab] and [cemiplimab …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …

Piroxicam

A cyclooxygenase inhibiting, non-steroidal anti-inflammatory agent (NSAID) that is well established in treating rheumatoid arthritis and osteoarthritis and used for musculoskeletal disorders, dysmenorrhea, and postoperative pain. Its long half-life enables it to be administered once daily.
Approved
Investigational
Matched Description: … osteoarthritis and used for musculoskeletal disorders, dysmenorrhea, and postoperative pain. ... non-steroidal anti-inflammatory agent (NSAID) that is well established in treating rheumatoid arthritis and …
Matched Categories: … Antiinflammatory and Antirheumatic Products ... Topical Products for Joint and Muscular Pain ... Antiinflammatory and Antirheumatic Products, Non-Steroids …

Nifurtimox

Chagas disease, caused by a parasite known as Trypanosoma cruzi (T.cruzi), is a vector-transmitted disease affecting animals and humans in the Americas. It is commonly known as American Trypanosomiasis. The CDC estimates that approximately 8 million people in Central America, South America, and Mexico are infected with T. cruzi, without...
Approved
Investigational
Matched Description: … a parasite known as Trypanosoma cruzi (T.cruzi), is a vector-transmitted disease affecting animals and ... L15366] The CDC estimates that approximately 8 million people in Central America, South America, and …
Matched Categories: … Agents Against Leishmaniasis and Trypanosomiasis ... Antiparasitic Products, Insecticides and Repellents …
Displaying drugs 2226 - 2250 of 15152 in total